CN107001264B - 作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物 - Google Patents

作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物 Download PDF

Info

Publication number
CN107001264B
CN107001264B CN201580053446.3A CN201580053446A CN107001264B CN 107001264 B CN107001264 B CN 107001264B CN 201580053446 A CN201580053446 A CN 201580053446A CN 107001264 B CN107001264 B CN 107001264B
Authority
CN
China
Prior art keywords
compound
chloro
general formula
methoxyphenyl
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580053446.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001264A (zh
Inventor
B.R.R.科斯特勒恩
J-F.邦范蒂
T.H.M.乔恩克斯
P.J-M.B.拉博伊斯森
D.A.M-E.巴迪奥特
A.D.M.马钱德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Janssen Pharmaceuticals Inc
Original Assignee
KU Leuven
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107001264(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KU Leuven, Janssen Pharmaceuticals Inc filed Critical KU Leuven
Publication of CN107001264A publication Critical patent/CN107001264A/zh
Application granted granted Critical
Publication of CN107001264B publication Critical patent/CN107001264B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580053446.3A 2014-10-01 2015-09-30 作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物 Active CN107001264B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14187374 2014-10-01
EP14187374.5 2014-10-01
EP15159164 2015-03-16
EP15159164.1 2015-03-16
PCT/EP2015/072551 WO2016050841A1 (en) 2014-10-01 2015-09-30 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (2)

Publication Number Publication Date
CN107001264A CN107001264A (zh) 2017-08-01
CN107001264B true CN107001264B (zh) 2021-06-15

Family

ID=54199687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580053446.3A Active CN107001264B (zh) 2014-10-01 2015-09-30 作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物

Country Status (32)

Country Link
US (1) US9944598B2 (enExample)
EP (1) EP3201176B1 (enExample)
JP (1) JP6732736B2 (enExample)
KR (1) KR102478311B1 (enExample)
CN (1) CN107001264B (enExample)
AU (1) AU2015326930B2 (enExample)
BR (1) BR112017006299A2 (enExample)
CA (1) CA2959573A1 (enExample)
CL (1) CL2017000782A1 (enExample)
CY (1) CY1121874T1 (enExample)
DK (1) DK3201176T3 (enExample)
EA (1) EA032546B1 (enExample)
ES (1) ES2714074T3 (enExample)
HR (1) HRP20190199T1 (enExample)
HU (1) HUE041888T2 (enExample)
IL (1) IL251396A0 (enExample)
LT (1) LT3201176T (enExample)
MA (1) MA40768B1 (enExample)
ME (1) ME03360B (enExample)
MX (1) MX2017004299A (enExample)
PH (1) PH12017500571A1 (enExample)
PL (1) PL3201176T3 (enExample)
PT (1) PT3201176T (enExample)
RS (1) RS58461B1 (enExample)
SG (1) SG11201702463YA (enExample)
SI (1) SI3201176T1 (enExample)
SM (1) SMT201900162T1 (enExample)
TW (1) TWI681951B (enExample)
UA (1) UA121119C2 (enExample)
UY (1) UY36340A (enExample)
WO (1) WO2016050841A1 (enExample)
ZA (1) ZA201702301B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
AU2015327345B9 (en) 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
BR112017006708A2 (pt) * 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
WO2017167953A1 (en) * 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) * 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) * 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CA3060583C (en) * 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
EP4720034A1 (en) * 2023-06-05 2026-04-08 Zydus Lifesciences Limited Novel compounds to treat viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024223A (zh) * 2011-09-26 2014-09-03 鲁汶天主教大学 病毒复制抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120049852A (ko) * 2009-06-30 2012-05-17 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024223A (zh) * 2011-09-26 2014-09-03 鲁汶天主教大学 病毒复制抑制剂

Also Published As

Publication number Publication date
CL2017000782A1 (es) 2017-11-03
UY36340A (es) 2016-04-01
JP2017531619A (ja) 2017-10-26
JP6732736B2 (ja) 2020-07-29
HRP20190199T1 (hr) 2019-04-05
TW201630879A (zh) 2016-09-01
PT3201176T (pt) 2019-03-04
WO2016050841A1 (en) 2016-04-07
TWI681951B (zh) 2020-01-11
LT3201176T (lt) 2019-03-25
MA40768A (fr) 2017-09-08
ZA201702301B (en) 2018-12-19
IL251396A0 (en) 2017-05-29
MA40768B1 (fr) 2019-03-29
CY1121874T1 (el) 2020-10-14
ME03360B (me) 2019-10-20
US9944598B2 (en) 2018-04-17
MX2017004299A (es) 2017-07-19
DK3201176T3 (en) 2019-03-25
SI3201176T1 (sl) 2019-05-31
CA2959573A1 (en) 2016-04-07
AU2015326930B2 (en) 2020-03-26
EP3201176B1 (en) 2018-12-12
CN107001264A (zh) 2017-08-01
PH12017500571A1 (en) 2017-08-30
EA201790758A1 (ru) 2017-07-31
SMT201900162T1 (it) 2019-05-10
EA032546B1 (ru) 2019-06-28
KR20170063802A (ko) 2017-06-08
UA121119C2 (uk) 2020-04-10
KR102478311B1 (ko) 2022-12-15
US20170298017A1 (en) 2017-10-19
EP3201176A1 (en) 2017-08-09
AU2015326930A1 (en) 2017-03-16
WO2016050841A9 (en) 2016-06-02
BR112017006299A2 (pt) 2018-01-16
ES2714074T3 (es) 2019-05-27
RS58461B1 (sr) 2019-04-30
SG11201702463YA (en) 2017-04-27
PL3201176T3 (pl) 2019-06-28
HUE041888T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
JP7451626B2 (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
JP6732736B2 (ja) デングウィルス複製阻害剤としての一または二置換インドール誘導体
CN107001265B (zh) 作为登革热病毒复制抑制剂的经单取代的或二取代的吲哚
JP6830438B2 (ja) デングウィルス複製阻害剤としてのインドール誘導体
JP2018528222A (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
HK1241874A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
HK1242299A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241874

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241874

Country of ref document: HK